Mouth

Enzychem Lifesciences Announces Positive Results for Phase 2 U.S. Study of EC-18 in Chemoradiation-Induced Oral Mucositis

Wednesday, October 20, 2021 - 1:00pm

Enzychem Lifesciences (KOSDAQ: 183490) announced today positive Phase 2 results from a U.S. clinical trial of its lead candidate EC-18 in chemoradiation-induced oral mucositis (CRIOM).

Key Points: 
  • Enzychem Lifesciences (KOSDAQ: 183490) announced today positive Phase 2 results from a U.S. clinical trial of its lead candidate EC-18 in chemoradiation-induced oral mucositis (CRIOM).
  • EC-18, a novel, first-in-class, small molecule oral immunomodulator, reduced the duration and incidence of severe oral mucositis in patients with head and neck cancer undergoing concurrent chemoradiation therapy.
  • Patients with the most severe form of oral mucositis often have to discontinue or modify their cancer treatment.
  • "We are delighted to announce these positive results from our Phase 2 U.S. study, which confirm that EC-18 is safe and well-tolerated, said Ki-Young Sohn, CEO & Chairman, Enzychem Lifesciences.

Drink Among Giants: Redwood Empire Whiskey Takes California Whiskey to New Heights

Wednesday, October 20, 2021 - 12:15pm

Redwood Empire Whiskey announces the release of its first collection of Bottled in Bond whiskeys: Redwood Empire Rocket Top Straight Rye Whiskey and Redwood Empire Grizzly Beast Straight Bourbon Whiskey.

Key Points: 
  • Redwood Empire Whiskey announces the release of its first collection of Bottled in Bond whiskeys: Redwood Empire Rocket Top Straight Rye Whiskey and Redwood Empire Grizzly Beast Straight Bourbon Whiskey.
  • These unique Bottled in Bond expressions continue to define Redwood Empire as a notable whiskey producer in the long-standing tradition of American spirits.
  • View the full release here: https://www.businesswire.com/news/home/20211020005104/en/
    Redwood Empire Whiskey announces the release of its first collection of Bottled in Bond whiskeys: Redwood Empire Rocket Top Straight Rye Whiskey and Redwood Empire Grizzly Beast Straight Bourbon Whiskey.
  • We started the Redwood Empire Whiskey project in 2011, first introducing our blended straight whiskey (Lost Monarch), then our Rye (Emerald Giant), and finally our Bourbon (Pipe Dream) in 2019.

Kedrion Biopharma to commercialize RYPLAZIM® (plasminogen, human-tvmh) in U.S. to address unmet need in patients with ultra-rare condition: Plasminogen Deficiency Type 1

Wednesday, October 20, 2021 - 12:00pm

"The most important mission at Kedrion Biopharma is to improve the lives of people with rare and serious diseases," said Kedrion Biopharma Chief Executive Officer, Val Romberg.

Key Points: 
  • "The most important mission at Kedrion Biopharma is to improve the lives of people with rare and serious diseases," said Kedrion Biopharma Chief Executive Officer, Val Romberg.
  • RYPLAZIM meets an urgent unmet medical need for people who face plasminogen deficiency type 1, a potentially devastating, but treatable, medical condition.
  • The Prometic deal also brings more cutting-edge purification technology to the Kedrion Biopharma group.
  • Kedrion Biopharma is ramping up RYPLAZIM production capacity to meet patient demand and anticipates RYPLAZIM will be available in limited quantities in 2022.

Free Shipping, Free Returns Beat Discounts and Promotions as Motivation for Holiday Spending, According to Consumer Insights From January Digital and Coresight Research

Tuesday, October 19, 2021 - 4:06pm
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20211019005877/en/
    According to consumer insights from January Digital and Coresight Research, health products, groceries and fashion will dominate their holiday shopping lists.
  • They are prioritizing health products, and they expect fast, free shipping and easy, free returns.
  • These findings align with our broader viewpoint on the upcoming holiday season, said Deborah Weinswig, CEO and founder, Coresight Research.
  • 1 The analysis presented in this report is based on findings from an online survey conducted by Coresight Research on August 29, 2021.

Galera Announces Results of Phase 3 ROMAN Trial of Avasopasem for Radiotherapy-Induced Severe Oral Mucositis

Tuesday, October 19, 2021 - 12:00pm

MALVERN, Pa., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced results from the Phase 3 ROMAN trial of avasopasem manganese (avasopasem) for severe oral mucositis (SOM) in patients with locally advanced head and neck cancer (HNC) undergoing standard-of-care radiotherapy. The trial did not meet its primary endpoint of reduction in the incidence of SOM. The Company is continuing to analyze the results.

Key Points: 
  • We recently initiated a Phase 2b trial of GC4711 in combination with SBRT in LAPC based on promising tumor and survival outcome benefits observed in a Phase 1/2 pilot trial.
  • In addition, enrollment is ongoing in a Phase 1/2 trial of GC4711 in combination with SBRT in patients with NSCLC.
  • The ROMAN trial is a randomized, double-blind, placebo-controlled trial in 455 patients with locally advanced HNC receiving seven weeks of standard-of-care radiotherapy plus cisplatin.
  • Oral mucositis is a side effect of radiation therapy characterized by severe pain, inflammation, ulceration and bleeding of the mouth.

Global Cone Beam Computed Tomography Market (2021 to 2028) - Size, Share & Trends Analysis Report

Tuesday, October 19, 2021 - 11:30am

DUBLIN, Oct. 19, 2021 /PRNewswire/ -- The "Cone Beam Computed Tomography Market Size, Share & Trends Analysis Report By Application (Dental Implantology, Orthodontics), By Patient Position (Seated Position, Standing Position), By End-use, And Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Oct. 19, 2021 /PRNewswire/ -- The "Cone Beam Computed Tomography Market Size, Share & Trends Analysis Report By Application (Dental Implantology, Orthodontics), By Patient Position (Seated Position, Standing Position), By End-use, And Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • The global cone beam computed tomography market size is expected to reach USD 1.07 billion by 2028, based on a new report by the publisher It is expected to expand at a CAGR of 12.2% from 2021 to 2028.
  • The market is driven by a rise in the volume of digital imaging procedures, especially in the field of dentistry.
  • Cone beam computed tomography (CBCT) produces a cone beam of radiation instead of a fan beam.

Minnesota Dental Association Warns Sour Treats May Cast Spell on Teeth

Monday, October 18, 2021 - 9:00pm

MINNEAPOLIS, Oct. 18, 2021 /PRNewswire/ -- This Halloween the Minnesota Dental Association advises treat-givers to make tooth-healthy choices and to pass on popular sour candy options. They might seem harmless, but these tricky treats may haunt teeth later on. 

Key Points: 
  • Brush two times a day using fluoride toothpaste and a soft toothbrush and don't forget to floss.
  • Most of all, protect teeth throughout the year by reducing or eliminating sour candies from your treat list.
  • The Minnesota Dental Association and its members have taken a national lead in educating parents, teachers, and children with a campaign called The Power of Sour on Your Teeth.
  • The Minnesota Dental Association is the voice of dentistry in Minnesota, representing practicing dentists.

Insights on the Cone Beam Computed Tomography Global Market to 2028 - by Application, Patient Position, End-use and Region - ResearchAndMarkets.com

Monday, October 18, 2021 - 5:36pm

Cone beam CT imaging is performed with the help of a rotating platform with the X-ray source and detector and uses a single flat panel.

Key Points: 
  • Cone beam CT imaging is performed with the help of a rotating platform with the X-ray source and detector and uses a single flat panel.
  • Cone beam computed tomography (CBCT) produces a cone beam of radiation instead of a fan beam.
  • The entire scanning process of the target area is done in a single rotation, hence reducing the radiation exposure significantly.
  • Asia Pacific is expected to witness the fastest growth over the forecast period due to the rising awareness about 3D imaging procedures and expanding healthcare infrastructure in the region
    4.3 Cone Beam Computed Tomography Market: Business Environment Analysis Tools
    Chapter 5 Cone Beam Computed Tomography Market: Application Analysis
    Chapter 6 Cone Beam Computed Tomography Market: Patient Position Analysis
    Chapter 7 Cone Beam Computed Tomography Market: End-Use Analysis
    Chapter 8 Cone Beam Computed Tomography Market: Regional Analysis
    9.1 Recent Developments & Impact Analysis, By Key Market Participants
    View source version on businesswire.com: https://www.businesswire.com/news/home/20211018005830/en/

PRECIsE Clinical Study Preliminary Results Favorable for Intuitive’s Ion Endoluminal System for Peripheral Nodule Lung Biopsy

Monday, October 18, 2021 - 2:05pm

The similarity between yield rates for both smaller and larger nodules biopsied with Ion is a favorable result for clinicians seeking to sample smaller nodules.

Key Points: 
  • The similarity between yield rates for both smaller and larger nodules biopsied with Ion is a favorable result for clinicians seeking to sample smaller nodules.
  • A strong safety profile: the Ion system had no serious adverse events reported in this subset of patients in the study, and no pneumothorax events requiring a chest tube.
  • These are encouraging results on the potential for this technology to help safely biopsy small lung nodules.
  • The system features an ultra-thin, ultra-maneuverable catheter that allows navigation far into the peripheral lung and provides the unprecedented stability necessary for precision in biopsy.

Vida Health becomes the only virtual care solution with 100% fees at risk for both physical and mental health

Monday, October 18, 2021 - 12:28pm

- Stephanie Tilenius, Vida Health Founder and CEO

Key Points: 
  • - Stephanie Tilenius, Vida Health Founder and CEO
    The new package was launched at HLTH 2021 in Boston, making Vida the first virtual healthcare provider to offer value-based pricing in both the physical and mental health space.
  • "Since the beginning we've prioritized delivering best-in-class physical and mental health outcomes in everything we build, from the product to the care teams and now the pricing model," said Vida Health Founder and CEO Stephanie Tilenius.
  • The new structure delivers care with fees at risk for clinical and engagement outcomes across the full spectrum of physical and mental health conditions Vida covers obesity, diabetes, hypertension, depression, anxiety, and more.
  • Vida Health is a virtual care company intentionally designed to treat mental and physical conditions together.